Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOP1630 in Moderate to Severe Dry Eye Syndrome
NCT03833388Phase 3Completed
- Sponsor
- TopiVert Pharma Limited
- Start
- Feb 2019
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of TOP1630 in dry eye syndrome (DED), sponsored by TopiVert Pharma Limited. Started Feb 2019; status: completed.
02
Drugs
TOP1630
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on NCT03833388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03833388.